Companies Overview

### Dubilicos Stallaaru

JUSTIN Capital goods and engineering: Early indications of bottoming of cycle < 11 >

Search News,Stock Quotes or Companie

You are here: Home » Companies » Financial X-Ray

## SHAPE THE **FUTURE OF PHARMA™** BECOME A MEMBER TODAY

## Valuations turning attractive for Dr Reddy's as company outperforms sector US price erosion, India growth trends would be keenly tracked

#### Topics

Dr Reddy's Laboratories | DRL | Pharma

Last Updated at March 1, 2022 18:05 IST







Ram Prasad Sahu | Mumbai





























## ALSO READ

Dr Reddy's Laboratories working on enhancing Covid-19 portfolio

TMS Ep58: Privatisation, Google smartwatch, RBI rates, encryption

Byju's ropes in ex-Bain

executive Rachna Bahadur to lead global expansion What is the road ahead for

Indian exports; will momentum continue? Germany's Boehringer,

Indian pharma in legal

battle over diabetes drug



since the start of CY22. The decline over this period was led by pricing headwinds in key markets, regulatory issues across multiple plant locations and its ability to sustain growth trajectory in focus markets. Near-term pressure on the stock is also due to the unfolding geopolitical situation and the impact on its sales to the affected regions. Russia and Ukraine account for 10 per cent (\$300

The Dr Reddy's Laboratories stock is down 17 per cent

million) of the company's overall revenues and near term growth may be hit due to the war. While receivables are \$100 million, most of it, according to the company, is hedged. On the Sputnik deal, Kotak Institutional Equities citing the company in a report says that there are no further imports required from Russia and there is no impact on the deal with RDIF for Sputnik V vaccine as of now.

For the US market perspective, the EIR or

Establishment Inspection Report for its Duvvada facility in Andhra Pradesh is positive and removes an overhang. The company had indicated last month that its formulation manufacturing facilities including an oncology injectable unit received the EIR from the US Food and Drug Administration (US FDA) indicating a closure of the inspection. The US FDA had inspected the site in October last year which resulted in a Form 483 with eight observations. With the

go ahead, the company will be launching multiple products from this site in FY23. While the price erosion (high single digit-low double digit) trends in the US are expected to

remain in the near term, the company is hoping to offset this with the launch of 25-30 products annually including complex products. This comes on the back of 80 products the company launched over the last three years. While there is no clarity on the launch of contraceptive Nuvaring, near-term opportunities include the generic version of Copaxone for multiple sclerosis and cancer drug Revlimid.

In addition to the US, its biggest market, the street will keep an eye on the growth trajectory in India and the emerging markets. The company, according to IIFL Research, is eyeing a top 5 position in the Indian pharma market from its current 12th position over the next five years led by organic and inorganic growth. The company has been outperforming the sector (23 per cent 27 per cent growth respectively in Q3 and January vs 18 per cent and 21 per cent of the pharma market) and the trend is expected to continue in the near term.

While there are near term challenges, at the current price, the stock is trading at attractive

# Read our full coverage on Dr Reddy's Laboratories

READ MORE ON DR REDDY'S LABORATORIES

First Published: Tue, March 01 2022. 18:05 IST

levels of under 18 times its FY23 earnings estimates.

PREVIOUS STORY

Honda Motorcycle total sales

drop 29% at 312,621 units in

FINANCIAL X-RAY

PHARMA

Hero MotoCorp sales dip 29% in Feb to 358,254 units, but exports rise

NEXT STORY


COMPANIES

# CultureOne™ Proven for GMP production Get the facts

IN THIS SECTION

**LATEST NEWS** 

ALL



owned vehicles, assets Honda Motorcycle total

sales drop 29% at 312,621

units in February

Shriram Automall India



Hero MotoCorp sales dip 29% in Feb to 358,254 units, but exports rise

Abu Dhabi's Etihad trims


losses on higher cargo

revenues, cost control



Reliance Retail invests in Abraham & Thakore for majority stake

More >



# MOST POPULAR

READ

SHARE

COMMENTED



ultra-rich count cost of \$83 bn wealth wipeout Zelensky to address

Ukraine crisis: Russia's



today Ashneer Grover resigns from BharatPe board amid boardroom battle


Parliament on Ukraine

session of European




after receiving Board meet agenda on PwC probe Turkey's Ilker Ayci declines

Ashneer Grover resigned




Air India CEO role in




#### Valuations turning attractive for Dr Reddy's as



company outperforms sector



Future looks bright for Hindalco, and Ukraine war may have a part to play



indications of bottoming of

More >

February